Neglected lymph nodal metastases in patients with renal cancer: when to extend the anatomical template of lymph node dissection during nephrectomy.
Adjuvant therapy
Kidney cancer
Renal cancer
Renal function
Survival
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
12
01
2023
accepted:
09
04
2023
medline:
7
6
2023
pubmed:
6
5
2023
entrez:
6
5
2023
Statut:
ppublish
Résumé
The role of lymph node dissection (LND) in patients with renal cell carcinoma (RCC) is still controversial. However, detecting lymph node invasion (LNI) is key due to prognostic implications and to identify patients who might benefit from adjuvant therapies such as adjuvant pembrolizumab. Out of 796 patients, 261 (33%) received eLND, of whom 62 (8%) for suspicious lymph node (LN) metastases at preoperative staging (cN1). eLND was divided in 3 anatomical areas: (1) hilar, (2) side-specific (pre-/para-aortic or pre-/para-caval) and (3) inter-aorto-caval nodes. Overall maximum LN diameter was measured by a dedicated radiologist for each patient. Multivariable logistic regression models (MVA) were tested for the effect of maximum LN diameter in predicting the presence of nodal metastases outside the anatomical area of cN1. LNI was confirmed in 50% of cN1, whilst only 13 out of 199 cN0 patients were pN1 at final histology (6.5%; p < 0.001). In a per-patient analysis, of 62 cN1 patients, 24% vs. 18% vs. 8% harboured pN1 disease only inside vs. in-outside vs. only outside the suspicious anatomical field of cN1 at preoperative CT/MRI scan. At MVA, increasing diameter of suspicious LNs was independently associated with risk of finding positive LNs outside the suspicious anatomical field (OR 1.05, 95%CI 1.02-1.11; p = 0.02). Roughly 50% of cN1 patients undergoing eLND will harbour LN metastases, also outside the suspicious radiological area, and maximum LNs diameter at preoperative imaging correlates with such risk. Thus, an eLND might be justified in patients with large suspicious LN metastases, to better stage this patient population and to improve postoperative treatment management.
Sections du résumé
BACKGROUND
BACKGROUND
The role of lymph node dissection (LND) in patients with renal cell carcinoma (RCC) is still controversial. However, detecting lymph node invasion (LNI) is key due to prognostic implications and to identify patients who might benefit from adjuvant therapies such as adjuvant pembrolizumab.
MATERIALS AND METHODS
METHODS
Out of 796 patients, 261 (33%) received eLND, of whom 62 (8%) for suspicious lymph node (LN) metastases at preoperative staging (cN1). eLND was divided in 3 anatomical areas: (1) hilar, (2) side-specific (pre-/para-aortic or pre-/para-caval) and (3) inter-aorto-caval nodes. Overall maximum LN diameter was measured by a dedicated radiologist for each patient. Multivariable logistic regression models (MVA) were tested for the effect of maximum LN diameter in predicting the presence of nodal metastases outside the anatomical area of cN1.
RESULTS
RESULTS
LNI was confirmed in 50% of cN1, whilst only 13 out of 199 cN0 patients were pN1 at final histology (6.5%; p < 0.001). In a per-patient analysis, of 62 cN1 patients, 24% vs. 18% vs. 8% harboured pN1 disease only inside vs. in-outside vs. only outside the suspicious anatomical field of cN1 at preoperative CT/MRI scan. At MVA, increasing diameter of suspicious LNs was independently associated with risk of finding positive LNs outside the suspicious anatomical field (OR 1.05, 95%CI 1.02-1.11; p = 0.02).
CONCLUSIONS
CONCLUSIONS
Roughly 50% of cN1 patients undergoing eLND will harbour LN metastases, also outside the suspicious radiological area, and maximum LNs diameter at preoperative imaging correlates with such risk. Thus, an eLND might be justified in patients with large suspicious LN metastases, to better stage this patient population and to improve postoperative treatment management.
Identifiants
pubmed: 37148324
doi: 10.1007/s00345-023-04413-z
pii: 10.1007/s00345-023-04413-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1573-1579Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Pagliara T, Nguyen A, Konety B (2014) Contemporary lymphadenectomy templates: kidney, prostate and bladder cancer. Curr Opin Urol 24:148–154. https://doi.org/10.1097/MOU.0000000000000026
doi: 10.1097/MOU.0000000000000026
pubmed: 24445555
Blom JHM, van Poppel H, Maréchal JM, Jacqmin D, Schröder FH, de Prijck L et al (2009) Radical Nephrectomy with and without Lymph-Node Dissection: Final Results of European Organization for Research and Treatment of Cancer (EORTC) Randomized Phase 3 Trial 30881. Eur Urol 55:28–34. https://doi.org/10.1016/j.eururo.2008.09.052
doi: 10.1016/j.eururo.2008.09.052
pubmed: 18848382
Crispen PL, Breau RH, Allmer C, Lohse CM, Cheville JC, Leibovich BC et al (2011) Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol 59:18–23. https://doi.org/10.1016/j.eururo.2010.08.042
doi: 10.1016/j.eururo.2010.08.042
pubmed: 20933322
Gershman B, Moreira DM, Thompson RH, Boorjian SA, Lohse CM, Costello BA et al (2017) Renal cell carcinoma with isolated lymph node involvement: long-term natural history and predictors of oncologic outcomes following surgical resection. Eur Urol 72:300–306. https://doi.org/10.1016/j.eururo.2016.12.027
doi: 10.1016/j.eururo.2016.12.027
pubmed: 28094055
Rosiello G, Palumbo C, Knipper S, Pecoraro A, Luzzago S, Tian Z et al (2020) Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma. Urol Oncol Semin Orig Investig 000:1–8. https://doi.org/10.1016/j.urolonc.2020.01.013
doi: 10.1016/j.urolonc.2020.01.013
Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A et al (2016) Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 375:2246–2254. https://doi.org/10.1056/NEJMoa1611406
doi: 10.1056/NEJMoa1611406
pubmed: 27718781
Capitanio UMD, Fallara GMD, Raggi DMD, Nocera LMD, Larcher AMD, Belladelli FMD et al (2022) Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence. Curr Probl Cancer 46:100875. https://doi.org/10.1016/j.currproblcancer.2022.100875
doi: 10.1016/j.currproblcancer.2022.100875
pubmed: 35679628
Capitanio U, Deho’ F, Dell’Oglio P, Larcher A, Capogrosso P, Nini A et al (2016) Lymphadenopathies in patients with renal cell carcinoma: clinical and pathological predictors of pathologically confirmed lymph node invasion. World J Urol 34:1139–1145. https://doi.org/10.1007/s00345-015-1747-5
doi: 10.1007/s00345-015-1747-5
pubmed: 26670425
Vickers AJ, Sjoberg DD (2015) Guidelines for reporting of statistics in European Urology. Eur Urol 67:181–187. https://doi.org/10.1016/j.eururo.2014.06.024
doi: 10.1016/j.eururo.2014.06.024
pubmed: 25037638
Rosiello G, Larcher A, Fallara G, Giancristofaro C, Martini A, Re C et al (2022) Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma. Urol Oncol. https://doi.org/10.1016/j.urolonc.2021.12.010
doi: 10.1016/j.urolonc.2021.12.010
pubmed: 36369233
Stabile A, Pellegrino A, Mazzone E, Cannoletta D, de Angelis M, Barletta F et al (2022) Can negative prostate-specific membrane antigen positron emission tomography/computed tomography avoid the need for pelvic lymph node dissection in newly diagnosed prostate cancer patients? A systematic review and meta-analysis with backup histology as reference standard. Eur Urol Oncol 5:1–17. https://doi.org/10.1016/j.euo.2021.08.001
doi: 10.1016/j.euo.2021.08.001
pubmed: 34538770
Ljubengigng et al (2022) Renal Cell Carcinoma EAU Guidelines on 2022
Vogel C, Ziegelmüller B, Ljungberg B, Bensalah K, Bex A, Canfield S et al (2019) Imaging in suspected renal-cell carcinoma: systematic review. Clin Genitourin Cancer 17:e345–e355. https://doi.org/10.1016/j.clgc.2018.07.024
doi: 10.1016/j.clgc.2018.07.024
pubmed: 30528378
Capitanio U, Pepe G, Incerti E, Larcher A, Trevisani F, Lucianò R et al (2021) The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial. Eur J Nucl Med Mol Imaging 48:554–560. https://doi.org/10.1007/s00259-020-04936-2
doi: 10.1007/s00259-020-04936-2
pubmed: 32638098
Motzer RJ, Ravaud A, Patard J-J, Pandha HS, George DJ, Patel A et al (2018) Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results. Eur Urol 73:62–68. https://doi.org/10.1016/j.eururo.2017.09.008
doi: 10.1016/j.eururo.2017.09.008
pubmed: 28967554
Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C et al (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (London, England) 387:2008–2016. https://doi.org/10.1016/S0140-6736(16)00559-6
doi: 10.1016/S0140-6736(16)00559-6
pubmed: 26969090
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang Y-H et al (2021) Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med 385:683–694. https://doi.org/10.1056/NEJMoa2106391
doi: 10.1056/NEJMoa2106391
pubmed: 34407342
Palumbo C, Knipper S, Dzyuba-Negrean C, Pecoraro A, Rosiello G, Tian Z et al (2020) Complication rates, failure to rescue and in-hospital mortality after cytoreductive nephrectomy in the older patients. J Geriatr Oncol 11:718–723. https://doi.org/10.1016/j.jgo.2019.06.005
doi: 10.1016/j.jgo.2019.06.005
pubmed: 31257163
Rosiello G, Larcher A, Fallara G, Cignoli D, Re C, Martini A et al (2022) A comprehensive assessment of frailty status on surgical, functional and oncologic outcomes in patients treated with partial nephrectomy––a large, retrospective, single-center study. Urol Oncol Semin Orig Investig 000:2–10. https://doi.org/10.1016/j.urolonc.2022.10.008
doi: 10.1016/j.urolonc.2022.10.008
Saitoh H, Nakayama M, Nakamura K, Satoh T (1982) Distant metastasis of renal adenocarcinoma in nephrectomized cases. J Urol 127:1092–1095. https://doi.org/10.1016/s0022-5347(17)54243-3
doi: 10.1016/s0022-5347(17)54243-3
pubmed: 7087014
Riquet M, Berna P, Brian E, Badia A, Vlas C, Bagan P et al (2009) Intrathoracic lymph node metastases from extrathoracic carcinoma: the place for surgery. Ann Thorac Surg 88:200–205. https://doi.org/10.1016/j.athoracsur.2009.04.005
doi: 10.1016/j.athoracsur.2009.04.005
pubmed: 19559225
Nini A, Larcher A, Cazzaniga W, Dell’Oglio P, Cianflone F, Muttin F et al (2019) The side and the location of the primary tumor does not affect the probability of lymph node invasion in patients with renal cell carcinoma. World J Urol 37:1623–1629. https://doi.org/10.1007/s00345-018-2573-3
doi: 10.1007/s00345-018-2573-3
pubmed: 30474699
Gandaglia G, Mazzone E, Stabile A, Pellegrino A, Cucchiara V, Barletta F et al (2022) Prostate-specific membrane antigen radioguided surgery to detect nodal metastases in primary prostate cancer patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection: results of a planned interim analysis of a prospective phase 2 study. Eur Urol 82:411–418. https://doi.org/10.1016/j.eururo.2022.06.002
doi: 10.1016/j.eururo.2022.06.002
pubmed: 35879127
Capitanio U, Becker F, Blute ML, Mulders P, Patard JJ, Russo P et al (2011) Lymph node dissection in renal cell carcinoma. Eur Urol 60:1212–1220. https://doi.org/10.1016/j.eururo.2011.09.003
doi: 10.1016/j.eururo.2011.09.003
pubmed: 21940096
Nocera L, Stolzenbach LF, Ruvolo CC, Wenzel M, Tian Z, Rosiello G et al (2021) Predicting the risk of pT3a stage in cT1 clear cell renal cell carcinoma. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 47:1187–1190. https://doi.org/10.1016/j.ejso.2020.10.040
doi: 10.1016/j.ejso.2020.10.040
Gershman B, Takahashi N, Moreira DM, Thompson RH, Boorjian SA, Lohse CM et al (2016) Radiographic size of retroperitoneal lymph nodes predicts pathological nodal involvement for patients with renal cell carcinoma: development of a risk prediction model. BJU Int 118:742–749. https://doi.org/10.1111/bju.13424
doi: 10.1111/bju.13424
pubmed: 26800148